Literature DB >> 11142563

Pruritus in patients with chronic human immunodeficiency virus, hepatitis B and C virus infections.

M Bonacini1.   

Abstract

AIM: The prevalence of pruritus was prospectively determined in 310 patients of whom 119 had hepatitis C virus infection, 91 hepatitis C virus and human immunodeficiency virus, 51 human immunodeficiency virus infection alone, 31 hepatitis B virus and human immunodeficiency virus coinfection and 18 were HBsAg carriers.
RESULTS: Patients in the first three groups were more likely to complain of itching (22%, 28% and 25%, respectively) than HBsAg carriers (8.2%, p=0.01. Laboratory data were not different between groups, except for the human immunodeficiency virus group, whose alkaline phosphatase levels were highest, and CD4 counts were lowest (median 30 cells/mm3). Patients with hepatitis C, including those with human immunodeficiency virus, had similar hepatitis C virus RNA levels in patients with or without pruritus. There was no difference in hepatic inflammation or fibrosis between those with and those without pruritus.
CONCLUSION: 20% of patients with chronic hepatitis C and 8% of hepatitis B patients complain of pruritus. Patients with pruritus have laboratory and histologic parameters comparable to those without.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11142563     DOI: 10.1016/s1590-8658(00)80847-6

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  9 in total

1.  Study of pruritus in chronic hepatitis C patients.

Authors:  Kazuyoshi Suzuki; Masaya Tamano; Yasumi Katayama; Toru Kuniyoshi; Kagemasa Kagawa; Hiroshi Takada; Kazutomo Suzuki
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

Review 2.  Cholestatic Itch: Our Current Understanding of Pathophysiology and Treatments.

Authors:  Ashley Vander Does; Cynthia Levy; Gil Yosipovitch
Journal:  Am J Clin Dermatol       Date:  2022-07-28       Impact factor: 6.233

3.  The prevalence of HCV antibodies in skin disease patients in Saudi Arabia.

Authors:  Mona Halawani; Amal Balbisi; Hend Alotaibi; Fahed Alsaif; Talal M Bakir
Journal:  Saudi Pharm J       Date:  2009-12-24       Impact factor: 4.330

Review 4.  Neural processing of itch.

Authors:  Tasuku Akiyama; E Carstens
Journal:  Neuroscience       Date:  2013-07-24       Impact factor: 3.590

Review 5.  Recent advances in the management of pruritus in chronic liver diseases.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2017-05-21       Impact factor: 5.742

6.  Pruritus is common in patients with chronic liver disease and is improved by nalfurafine hydrochloride.

Authors:  Shuhei Yoshikawa; Takeharu Asano; Mina Morino; Keita Matsumoto; Hitomi Kashima; Yudai Koito; Takaya Miura; Yuko Takahashi; Rumiko Tsuboi; Takehiro Ishii; Haruka Otake; Junichi Fujiwara; Masanari Sekine; Takeshi Uehara; Kazuhito Yuhashi; Satohiro Matsumoto; Shinichi Asabe; Hiroyuki Miyatani; Hirosato Mashima
Journal:  Sci Rep       Date:  2021-02-04       Impact factor: 4.379

7.  Post-Marketing Surveillance Study of the Safety and Efficacy of Nalfurafine (Capsules 2.5 μg, Oral Dispersing Tablets 2.5 μg) in 1186 Patients with Chronic Liver Disease and Intractable Pruritus.

Authors:  Hiroshi Yoshitani; Junko Ito; Hideki Kozono
Journal:  Hepat Med       Date:  2022-05-02

8.  Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis.

Authors:  Hatsue Fujino; Mio Tanaka; Michio Imamura; Kei Morio; Atsushi Ono; Takashi Nakahara; Eisuke Murakami; Tomokazu Kawaoka; Shoichi Takahashi; Daiki Miki; Masataka Tsuge; Akira Hiramatsu; Hiroshi Aikata; C Nelson Hayes; Kazuaki Chayama
Journal:  BMC Gastroenterol       Date:  2019-10-24       Impact factor: 3.067

Review 9.  Chronic Kidney Disease-Associated Itch (CKD-aI) in Children-A Narrative Review.

Authors:  Radomir Reszke; Katarzyna Kiliś-Pstrusińska; Jacek C Szepietowski
Journal:  Toxins (Basel)       Date:  2021-06-29       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.